NCT03349697 is a Phase 2 clinical trial of Phyllantus amarus in Healthy, sponsored by Biotropics Malaysia Berhad.

Who is sponsoring NCT03349697?

NCT03349697 is sponsored by Biotropics Malaysia Berhad.

What drugs are being tested in NCT03349697?

Interventions in NCT03349697: Phyllantus amarus, Placebo.

Is NCT03349697 still recruiting?

NCT03349697 is currently completed. Last updated 27 November 2017.

Last reviewed 2017-11-27 · How we verify

NCT03349697

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Phyllantus Amarus for the Protection of Liver Health

Completed Phase 2 Last updated 27 November 2017

What this trial tests

Phase 2 trial testing Phyllantus amarus in Healthy in 15 participants. Completed in 16 October 2010.

Timeline

13 July 2010

Primary endpoint
16 October 2010

16 October 2010

Quick facts

Lead sponsor	Biotropics Malaysia Berhad
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	quadruple
Primary purpose	prevention
Enrollment	15
Start date	13 July 2010
Primary completion	16 October 2010
Estimated completion	16 October 2010
Sites	1 location across United States

Drugs / interventions tested

Phyllantus amarus
Placebo

Conditions studied

Healthy — all drugs for Healthy →

Sponsor

Biotropics Malaysia Berhad

Who can join

Adults 21 to 50, any sex, with Healthy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is a randomized, double-blind, placebo controlled crossover study. The purpose of this study is to assess the ability of Phyllantus amarus to protect the liver against temporary stress including oxidative stress induced by alcohol consumption.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Effects of Phyllanthus amarus PHYLLPRO<sup>TM</sup> leaves on hangover symptoms: a randomized, double-blind, placebo-controlled crossover study.
George A, Udani JK, Yusof A. · · 2019 · cited 11× · PMID 30922154 · DOI 10.1080/13880209.2019.1585460

Verify or expand the search:

Other recruiting trials for Healthy

Currently open trials in the same condition.

NCT06707207 — Predicting Future Errors During Skill Performance · recruiting
NCT07169630 — PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI) · Phase 1 · recruiting
NCT07499414 — The Effects of the Bile Acid Supplement, 7-keto Lithocholic Acid, on Human Gut Microbiota and Risk Factors for Disease. · NA · recruiting
NCT07496697 — Effects of Electroacupuncture at NP82 and SP15 on Bowel Motility in Healthy Subjects · NA · recruiting
NCT06431932 — Pilot Trial of Fisetin in Healthy Volunteers and Older Patients With Multimorbidity · Phase 1, PHASE2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03349697 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Biotropics Malaysia Berhad
Last refreshed: 27 November 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03349697.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing